You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival
|
|---|---|
| Published in |
Cell Death & Differentiation, January 2011
|
| DOI | 10.1038/cdd.2010.164 |
| Pubmed ID | |
| Authors |
E A Afanasyeva, P Mestdagh, C Kumps, J Vandesompele, V Ehemann, J Theissen, M Fischer, M Zapatka, B Brors, L Savelyeva, V Sagulenko, F Speleman, M Schwab, F Westermann |
| Abstract |
Several microRNA (miRNA) loci are found within genomic regions frequently deleted in primary neuroblastoma, including miR-885-5p at 3p25.3. In this study, we demonstrate that miR-885-5p is downregulated on loss of 3p25.3 region in neuroblastoma. Experimentally enforced miR-885-5p expression in neuroblastoma cell lines inhibits proliferation triggering cell cycle arrest, senescence and/or apoptosis. miR-885-5p leads to the accumulation of p53 protein and activates the p53 pathway, resulting in upregulation of p53 targets. Enforced miR-885-5p expression consistently leads to downregulation of cyclin-dependent kinase (CDK2) and mini-chromosome maintenance protein (MCM5). Both genes are targeted by miR-885-5p via predicted binding sites within the 3'-untranslated regions (UTRs) of CDK2 and MCM5. Transcript profiling after miR-885-5p introduction in neuroblastoma cells reveals alterations in expression of multiple genes, including several p53 target genes and a number of factors involved in p53 pathway activity. Taken together, these data provide evidence that miR-885-5p has a tumor suppressive role in neuroblastoma interfering with cell cycle progression and cell survival. |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 2 | 3% |
| Spain | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 66 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 26% |
| Student > Ph. D. Student | 13 | 19% |
| Student > Doctoral Student | 5 | 7% |
| Student > Master | 4 | 6% |
| Other | 3 | 4% |
| Other | 10 | 14% |
| Unknown | 17 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 23 | 33% |
| Biochemistry, Genetics and Molecular Biology | 15 | 21% |
| Medicine and Dentistry | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Veterinary Science and Veterinary Medicine | 2 | 3% |
| Other | 7 | 10% |
| Unknown | 17 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2021.
All research outputs
#5,313,206
of 24,946,857 outputs
Outputs from Cell Death & Differentiation
#1,072
of 3,131 outputs
Outputs of similar age
#34,520
of 193,748 outputs
Outputs of similar age from Cell Death & Differentiation
#8
of 25 outputs
Altmetric has tracked 24,946,857 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,131 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.9. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,748 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.